145 related articles for article (PubMed ID: 25971265)
21. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting.
Altman JK; Szilard A; Goussetis DJ; Sassano A; Colamonici M; Gounaris E; Frankfurt O; Giles FJ; Eklund EA; Beauchamp EM; Platanias LC
Clin Cancer Res; 2014 May; 20(9):2400-9. PubMed ID: 24610825
[TBL] [Abstract][Full Text] [Related]
22. mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression.
Sticz T; Molnár A; Márk Á; Hajdu M; Nagy N; Végső G; Micsik T; Kopper L; Sebestyén A
J Clin Pathol; 2017 May; 70(5):410-416. PubMed ID: 27729429
[TBL] [Abstract][Full Text] [Related]
23. Loss of Dnmt3b accelerates MLL-AF9 leukemia progression.
Zheng Y; Zhang H; Wang Y; Li X; Lu P; Dong F; Pang Y; Ma S; Cheng H; Hao S; Tang F; Yuan W; Zhang X; Cheng T
Leukemia; 2016 Dec; 30(12):2373-2384. PubMed ID: 27133822
[TBL] [Abstract][Full Text] [Related]
24. PIH1D1 interacts with mTOR complex 1 and enhances ribosome RNA transcription.
Kamano Y; Saeki M; Egusa H; Kakihara Y; Houry WA; Yatani H; Kamisaki Y
FEBS Lett; 2013 Oct; 587(20):3303-8. PubMed ID: 24036451
[TBL] [Abstract][Full Text] [Related]
25. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
26. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
27. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
28. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.
Reikvam H; Tamburini J; Skrede S; Holdhus R; Poulain L; Ersvaer E; Hatfield KJ; Bruserud Ø
Br J Haematol; 2014 Jan; 164(2):200-11. PubMed ID: 24383842
[TBL] [Abstract][Full Text] [Related]
29. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent.
Cheng F; Wang L; Shen Y; Xia J; Chen H; Jiang Y; Lu M
Biochem Biophys Res Commun; 2016 Feb; 470(2):324-330. PubMed ID: 26792718
[TBL] [Abstract][Full Text] [Related]
31. mTORC1 controls PNS myelination along the mTORC1-RXRγ-SREBP-lipid biosynthesis axis in Schwann cells.
Norrmén C; Figlia G; Lebrun-Julien F; Pereira JA; Trötzmüller M; Köfeler HC; Rantanen V; Wessig C; van Deijk AL; Smit AB; Verheijen MH; Rüegg MA; Hall MN; Suter U
Cell Rep; 2014 Oct; 9(2):646-60. PubMed ID: 25310982
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.
Schneider E; Staffas A; Röhner L; Krowiorz K; Heuser M; Döhner K; Bullinger L; Döhner H; Fogelstrand L; Rouhi A; Kuchenbauer F; Palmqvist L
Exp Hematol; 2016 Dec; 44(12):1166-1171. PubMed ID: 27619068
[TBL] [Abstract][Full Text] [Related]
33. Rictor/mammalian target of rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3.
Hua C; Guo H; Bu J; Zhou M; Cheng H; He F; Wang J; Wang X; Zhang Y; Wang Q; Zhou J; Cheng T; Xu M; Yuan W
Exp Hematol; 2014 Dec; 42(12):1031-40.e1-4. PubMed ID: 25201756
[TBL] [Abstract][Full Text] [Related]
34. SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model.
Täger M; Horn S; Latuske E; Ehm P; Schaks M; Nalaskowski M; Fehse B; Fiedler W; Stocking C; Wellbrock J; Jücker M
Gene Ther; 2017 Nov; 24(11):749-753. PubMed ID: 29143813
[TBL] [Abstract][Full Text] [Related]
35. Mammalian target of rapamycin complex 2 signaling pathway regulates transient receptor potential cation channel 6 in podocytes.
Ding F; Zhang X; Li X; Zhang Y; Li B; Ding J
PLoS One; 2014; 9(11):e112972. PubMed ID: 25393730
[TBL] [Abstract][Full Text] [Related]
36. P2X7 promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of Pbx3.
Feng W; Yang X; Wang L; Wang R; Yang F; Wang H; Liu X; Ren Q; Zhang Y; Zhu X; Zheng G
Haematologica; 2021 May; 106(5):1278-1289. PubMed ID: 32165482
[TBL] [Abstract][Full Text] [Related]
37. [Co-activation of AMPK and mTORC1: a therapeutic application of synthetic lethality in acute myeloid leukemia].
Tamburini J; Poulain L; Bouscary D; Sujobert P
Med Sci (Paris); 2015 Oct; 31(10):836-9. PubMed ID: 26481022
[No Abstract] [Full Text] [Related]
38. mTORC1 Signaling Promotes Osteoblast Differentiation from Preosteoblasts.
Chen J; Long F
PLoS One; 2015; 10(6):e0130627. PubMed ID: 26090674
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.
Wazir U; Newbold RF; Jiang WG; Sharma AK; Mokbel K
Oncol Rep; 2013 May; 29(5):1969-74. PubMed ID: 23503572
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
Tao YF; Li ZH; Du WW; Xu LX; Ren JL; Li XL; Fang F; Xie Y; Li M; Qian GH; Li YH; Li YP; Li G; Wu Y; Feng X; Wang J; He WQ; Hu SY; Lu J; Pan J
Oncol Rep; 2017 Mar; 37(3):1419-1429. PubMed ID: 28184925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
